InvestSMART

MGC Pharmaceuticals Ltd (ASX: MXC) - Announcements

Current share price for MXC : $0.420 0.01 (2.44%)+

ASX company news and announcements for MGC Pharmaceuticals Ltd (MXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All MGC Pharmaceuticals Ltd (MXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than MGC Pharmaceuticals Ltd (MXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for MGC Pharmaceuticals Ltd (MXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Harvey Nichols To Sell MGC Derma and Derma Plus Cosmetics 12 Jun 2018 9:58AM $0.063 $0.420 risen by 566.67%
$18 Appendix 3Y - Change of Director's Interest Notice x 2 24 May 2018 4:42PM $0.071 $0.420 risen by 491.55%
$18 Maltese Government Approves Medicinal Cannabis Legislation 21 May 2018 9:42AM $0.069 $0.420 risen by 508.70%
$18 Exercise of 6.5c Listed Options - Appendix 3B 18 May 2018 5:50PM $0.069 $0.420 risen by 508.70%
$18 Investor Presentation - May 2018 15 May 2018 9:51AM $0.073 $0.420 risen by 475.34%
$18 Corporate Update - CEO steps into Managing Director role 15 May 2018 9:44AM $0.073 $0.420 risen by 475.34%
$18 MGC Derma launches Second Derma Plus CBD Product 10 May 2018 9:52AM $0.074 $0.420 risen by 467.57%
$18 March Quarterly Activity and Cashflow Report 30 Apr 2018 5:39PM $0.077 $0.420 risen by 445.45%
$18 $5m Placement Completed - Cleansing Notice & Appendix 3B 17 Apr 2018 6:10PM $0.086 $0.420 risen by 388.37%
$18 Malta Govt Approval for MC Licensed Facility 12 Apr 2018 11:15AM $0.084 $0.420 risen by 400%
$18 $5m Placement at 7.0c Closed Stongly Oversubscribed 11 Apr 2018 10:07AM $0.075 $0.420 risen by 460%
$18 Contract Secured for Full MC Production Facility in Malta 11 Apr 2018 10:06AM $0.075 $0.420 risen by 460%
$18 Trading Halt 9 Apr 2018 9:31AM $0.075 $0.420 risen by 460%
$18 Production of First CannEpil Batch Commences at EU Facility 29 Mar 2018 9:44AM $0.084 $0.420 risen by 400%
$18 Appendix 3B 23 Mar 2018 6:00PM $0.087 $0.420 risen by 382.76%
$18 MXC Launches MGC Nutraceuticals Product Line 13 Mar 2018 9:34AM $0.094 $0.420 risen by 346.81%
$18 Updated MXC Operational and Strategy Update 5 Mar 2018 9:42AM $0.089 $0.420 risen by 371.91%
$18 MXC Operational and Strategy Update 5 Mar 2018 9:29AM $0.089 $0.420 risen by 371.91%
$18 Issue of Unlisted Options - Appendix 3B 5 Mar 2018 8:20AM $0.089 $0.420 risen by 371.91%
$18 Change of Registered Office 2 Mar 2018 2:39PM $0.089 $0.420 risen by 371.91%
$18 Release of Shares from Escrow - Appendix 3B 2 Mar 2018 2:36PM $0.089 $0.420 risen by 371.91%
$18 Half Yearly Report and Accounts 26 Feb 2018 8:04AM $0.100 $0.420 risen by 320%
$18 Exercise of 6.5c Listed Options - Appendix 3B 16 Feb 2018 3:54PM $0.110 $0.420 risen by 281.82%
$18 MXC Derma Products Officially Launched on Cult Beauty Online 14 Feb 2018 9:31AM $0.110 $0.420 risen by 281.82%
$18 Restricted Securities to be Released from Escrow 9 Feb 2018 3:21PM $0.103 $0.420 risen by 309.76%

626 - 650 of 818 results

Page 26 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.